A measure of SRS/SRT plan quality: Quantitative limits for intermediate dose spill (R50%) in linac-based delivery.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of applied clinical medical physics"
DOI: 10.1002/acm2.13570
Abstract: Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) of multiple cranial targets using a single isocenter on conventional C-arm linear accelerators are rapidly developing clinical techniques. However, no universal guidelines for acceptable intermediate dose spill limits… read more here.
Keywords: intermediate dose; srs srt; dose spill;
How to estimate R50% for cranial SRS/SRT cases with overlapping 50% isodose volumes: A proposed system
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Applied Clinical Medical Physics"
DOI: 10.1002/acm2.13624
Abstract: Abstract Inevitably in clinical stereotactic cranial single isocenter multiple target cases treated with linac‐based multi‐leaf collimated (MLC) delivery, one encounters planning target volumes (PTVs) in close proximity with overlapping 50% isodose clouds (IDC50%). In such… read more here.
Keywords: system; overlapping isodose; dose spill; intermediate dose ... See more keywords
The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition
Sign Up to like & getrecommendations! Published in 2022 at "Acta Haematologica"
DOI: 10.1159/000528736
Abstract: Background: Management of anticoagulant therapy in COVID-19 patients is critical. Low-molecular-weight heparin (LMWH) thromboprophylaxis is already recommended, and anti-Factor Xa (anti-FXa) monitoring has been used to titrate LMWH doses. Methods: Through a cross-sectional study, we… read more here.
Keywords: dose group; dose; anti fxa; therapeutic dose ... See more keywords
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin
Sign Up to like & getrecommendations! Published in 2022 at "Phlebology"
DOI: 10.1177/02683555221143576
Abstract: Objectives To evaluate the risk of symptomatic venous thromboembolism (VTE) recurrence at 3 months in relation to treatment duration, according to baseline risk factor profiles, in patients with superficial vein thrombosis (SVT) treated with intermediate… read more here.
Keywords: vein thrombosis; treatment duration; risk; treatment ... See more keywords
Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies—The PACER-VARP Registry
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296211016550
Abstract: The management of pregnant women at increased risk of thromboembolic/other vascular events is still a matter of debate. In a single-center, retrospective, observational trial, we analyzed the safety and efficacy of prophylactic anticoagulation with certoparin… read more here.
Keywords: anticoagulation; risk; intermediate dose; prophylactic anticoagulation ... See more keywords
Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study
Sign Up to like & getrecommendations! Published in 2023 at "Vascular"
DOI: 10.1177/17085381231165083
Abstract: Introduction The high prevalence of deep vein thrombosis (DVT) in patients admitted to intensive care unit (ICU) for COVID-19-related acute respiratory distress syndrome (ARDS) would justify systematic screening of these patients or higher therapeutic dose… read more here.
Keywords: dose heparin; dvt; covid; intermediate dose ... See more keywords
Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2020.267526
Abstract: The outcome of acute myeloid leukemia (AML) is affected by disease characteristics as well as treatment regimens. In the CALGB8525 trial, patients with core binding factor (CBF)-positive leukemia benefited from consolidation with a high dose… read more here.
Keywords: intermediate dose; transplantation; dose cytarabine; group ... See more keywords